Comparative Pharmacology
Head-to-head clinical analysis: AVACLYR versus PHEXXI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVACLYR versus PHEXXI.
AVACLYR vs PHEXXI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytidine analog nucleoside metabolic inhibitor; inhibits respiratory syncytial virus (RSV) RNA polymerase, thereby inhibiting viral RNA synthesis.
PHEXXI is a vaginal gel containing lactic acid, citric acid, and potassium bitartrate that maintains acidic vaginal pH, which inactivates sperm and reduces sperm motility and viability.
2.5 mg subcutaneously once weekly
Intravaginal gel: 1 applicatorful (5 g of gel containing 1.3% lactic acid, 0.01% citric acid, and 0.3% potassium bitartrate) inserted once daily at bedtime for 7 days, or as directed by physician.
None Documented
None Documented
Terminal half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl 30-49 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 30-60 minutes; clinically, rapid clearance reduces systemic toxicity, requiring repeated administration for sustained effect.
Renal (90% as unchanged drug, <2% as metabolite); fecal <2%.
Primarily renal excretion as unchanged drug (70-80%) and metabolites; remainder biliary/fecal. Renal clearance approximates glomerular filtration rate.
Category C
Category C
Topical Antiviral
Topical Antiviral